Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day
22 juin 2018 09h12 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release...
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
24 mai 2018 09h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pharmacokinetic (PK) data regarding GOCOVRI™ (amantadine) extended release...
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
19 avr. 2018 05h30 HE
|
Adamas Pharmaceuticals, Inc.
-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif.,...
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
12 avr. 2018 17h09 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced it will make six data presentations at the 70th Annual Meeting of the American...
Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
15 mars 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules for the...
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
08 févr. 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
02 nov. 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30,...
Adamas to Host Investor and Analyst Meeting on September 18, 2017
13 sept. 2017 16h53 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from...
Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results
08 août 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. ...
Adamas Appoints New Chief Financial Officer
28 juin 2017 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to...